April 07, 2021 1 min read ADD SUBJECT TO E-MAIL SIGNALS Receive an e-mail when brand-new articles are published on Please supply your email address to receive an email when new posts are posted on.
CONTRIBUTED TO E-MAIL NOTIFIES
We were unable to process your demand. Please try once again later. If you continue to have this concern please contact email@example.com.
Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device has actually gotten FDA approval for use in ophthalmic surgery, according to a news release.
ClearVisc safeguards the cornea from thermal and mechanical damage, and includes sorbitol, which provides totally free extreme defense, reducing risk of corneal damage and decompensation throughout cataract extraction and implantation of IOLs, according to the release.
The item was evaluated in a multicenter randomized medical study of 372 topics. ClearVisc produced no major unfavorable occasions and fulfilled its primary safety and efficacy endpoints.
“OVDs play a critical function in cataract surgery along with lots of other ophthalmic surgical treatments,” Joe Gordon, U.S. president of Bausch + Lomb, stated in the release. “ClearVisc uses considerable benefits that can help cosmetic surgeons provide the very best possible outcomes for their clients.”
ADD SUBJECT TO EMAIL INFORMS
Get an e-mail when brand-new articles are posted on
Please supply your e-mail address to receive an email when new articles are posted on.
ADDED TO EMAIL NOTIFIES
We were not able to process your demand. Please try again later on. If you continue to have this issue please contact firstname.lastname@example.org.